Lisa Cook sues Trump over firing attempt, emergency hearing set
Tempus AI, Inc. (NASDAQ:TEM) filed a prospectus supplement with the U.S. Securities and Exchange Commission on Wednesday covering the potential resale of up to 1,268,033 shares of its Class A common stock by certain selling stockholders. The company’s Class A common stock has a par value of $0.0001 per share.
According to the filing, the prospectus supplement was submitted as part of an automatic shelf registration statement on Form S-3, originally filed on August 8. The purpose of the supplement is to allow the referenced stockholders to resell their shares on the open market if they choose.
Tempus AI also provided a legal opinion from its counsel, Brownstein Hyatt Farber Schreck, LLP, concerning the legality of the shares included in the prospectus supplement. This opinion was attached to the filing as Exhibit 5.1.
The company is incorporated in Nevada and is headquartered in Chicago, Illinois. The filing was signed by James Rogers, Chief Financial Officer.
All information in this article is based on a statement made in a press release filed with the SEC.
In other recent news, Tempus AI Inc. reported impressive second-quarter 2025 earnings, with revenue reaching $314.6 million, surpassing the forecast of $297.8 million. The company also reported a narrower-than-expected loss per share at -$0.22, compared to the anticipated -$0.25. Following these results, BTIG raised its price target for Tempus AI to $85 from $75, maintaining a Buy rating, highlighting the company’s 36% year-over-year growth in data revenue and 33% growth in core genomics revenue. Additionally, TD Cowen increased its price target to $72 from $62, citing stronger genomic volumes and a positive outlook for Tempus AI’s Ambry business.
Meanwhile, Stifel maintained a Hold rating on the stock, keeping its price target at $65. Furthermore, Tempus AI announced the acquisition of Paige, an AI digital pathology firm, for $81.25 million. This acquisition will be paid mainly in Tempus common stock and includes assuming Paige’s commitments under its Microsoft Azure cloud services agreement. This deal grants Tempus access to Paige’s extensive dataset of nearly 7 million digitized pathology slide images from 45 countries.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.